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INTERLEUKIN 17- RECEPTOR A (IL-17RA) ON
LEUKOCYTES AND TISSUE CELLS MEDIATES
INFLAMMATION IN A MURINE MODEL OF
CRESCENTIC GLOMERULONEPHRITIS
J GHALI, S HOLDSWORTH, R KITCHING
Monash Medical Centre, Australia
Aim: To explore the role of IL-17RA in experimental crescentic glomerulone-
phritis (GN).
Background: Interleukin (IL)-17A and IL-17F are inflammatory cytokines
which signal through IL-17 receptor A (IL-17RA), expressed on many cell types,
including renal tissue cells.
Methods: Necrotising, crescentic GN was induced by intravenous administra-
tion of sheep anti-mouse glomerular basement membrane globulin, thereby plant-
ing sheep globulin (SG) in glomeruli. Mice were culled at day 21. Wild type
C57BL/6 (WT), IL-17RA-/- and bone marrow chimeric mice were used.
Results: IL-17RA-/- mice had reduced crescent formation (WT 17  3 vs
IL-17RA-/- 9  3% P < 0.05), with fewer glomerular neutrophils (1.2  0.1 vs
0.76  0.04 cells/glomerular cross section [c/gcs]; P < 0.05), macrophages
(2.0  0.2 vs 1.1  0.2c/gcs; P < 0.05) and a trend towards fewer T cells
(0.25  0.1 vs 0.15  0.1c/gcs; P = NS). IL-17RA-/- mice had lower circulating
anti-SG antibodies than WT mice (OD450 1:100; 0.3  0.1 vs 0.2  0.0;
P < 0.05).
Bone marrow chimeric mice (chimerism 96%) were generated, permitting
assessment of the effects of selective IL-17RA deficiency in either bone marrow
(BM) or tissue cells (TC). BM-TC+ mice had reduced glomerular segmental
necrosis (BM+TC+ 49  5 vs BM-TC+ 27  5; P < 0.05) and urinary protein:
creatinine ratios (BM+TC + 2.0  0.3 vs BM-TC + 1.1  0.3 mg/mmol;
P < 0.05). Mice with BM or TC IL-17RA deficiency had impaired cellular immu-
nity (ELISPOT: BM+TC + 91  19 vs BM-TC + 41  6 IFNg+ spots/2 ¥ 106
SG-stimulated splenocytes; BM+TC + 91  19 vs BM+TC- 43  8; both
P < 0.05).
Conclusion: IL-17A/F signalling promotes glomerular injury. Leukocyte-derived
IL-17RA promotes immunity and injury, while IL-17RA on radio-resistant cells
enhances antigen-specific systemic immunity.
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SHORT AND LONG TERM BIOLOGICAL
VARIATION OF HIGH SENSITIVITY TROPONIN
T (HS-TnT) AND N-TERMINAL B-TYPE
NATRIURETIC PEPTIDE (NT-PROBNP) IN
THE STABLE DIALYSIS POPULATION
M FAHIM1, A HAYEN2, A COBURN3, G DIMESKI4, D JOHNSON3,
J CRAIG5, A RITA HORVATH6, S CAMPBELL3, C HAWLEY3
1The University of Queensland at Princess Alexandra Hospital, Australia; 2The
University of New South Wales, Australia; 3Princess Alexandra Hospital, Australia;
4Pathology Queensland, Australia; 5Westmead Children’s Hospital, Australia;
6Prince of Wales Hospital, Australia
Aims: To determine the within-person(biological) variation of hs-TnT and
NT-proBNP in stable dialysis patients, and derive the difference between serial
measurements needed to detect a clinically significant change with 90% certain-
ty(RCV).
Background: hs-TnT is frequently measured in the dialysis population for the
diagnosis of acute cardiac events, and NT-proBNP is an emerging biomarker of
long-term cardiac-risk, but their underlying biological variation in this setting is
unknown; leading to misinterpretation of serial measurements.
Methods: Multicentre, prospective cohort study. 55 prevalent HD and PD
patients(1:1) were assessed 10-times: weekly for 5-weeks then monthly for
4-months. Assessments were conducted at the same dialysis-cycle time point
and entailed clinical review, bioimpedance spectroscopy, ECG, hs-TnT and
NT-proBNP testing. Batched samples underwent duplicate analysis in a single-
run. Patients were excluded if they underwent a change in cardiac medication,
dialysis prescription, ischaemic symptomatology, extracellular volume >1 L, new
arrhythmia or hospitalisation between visits. Between-person(CVG) and within-
person(CVI) coefficients of variation were estimated using nested analysis of
variance.
Results: 136-weekly and 113-monthly intervals from 42 patients were
able to be included (age:59  15 yrs, coronary-artery disease = 22%, LV
ejection fraction = 60  7%, diastolic dysfunction = 86%). For NT-proBNP:
Median = 1974 pg/mL, CVG = 152%, CVI-weekly = 27% and CVI-monthly = 35%,
RCVweekly = -46%–+84%, RCVmonthly = -54%–+120%, CVI : CVG = 0.23. For
hs-TnT: Median = 34 ng/L, CVG = 81%, CVI-weekly = 7.9% and CVI-monthly =
12.6%, RCVweekly = -17%–+20%, RCVmonthly = -25%–+34%, CVI : CVG = 0.16.
CVI was consistent across cardiac comorbidity subgroups.
Conclusions: Serial NT-proBNP levels need to double or halve and hs-TnT
levels must increase by 20–34% or fall by 17–25% to confidently exclude change
due to analytical & biological variation alone. The low CVI : CVG implies the
best strategy for applying these biomarkers in dialysis is relative change monitor-
ing after a baseline estimate rather than comparing results to reference intervals.
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BLOCKING THE NADPH OXIDASE Nox4 ACTIVITY
PROVIDES RENOPROTECTION IN LONG TERM
DIABETIC NEPHROPATHY
J JHA1, SP GRAY1, K WINGLER2, C SZYNDRALEWIEZ3, F HEITZ3,
ME COOPER4, H HHW SCHMIDT2, KA JANDELEIT-DAHM4
1Baker IDI Heart & Diabetes Institute, Australia; 2Department of Pharmacology,
Cardiovascular Research Institute Maastricht (CARIM), Netherlands; 3Genkyotex
SA, Switzerland; 4Diabetic Complications Division, Baker IDI Heart & Diabetes
Institute, Australia
Aim: To examine the role of the NADPH oxidase Nox1 and Nox4 in diabetic
nephropathy (DN) using genetic deletion and pharmacological inhibition
approaches in streptozotocin induced diabetic mice.
Background: Chronic kidney failure is a major complication of diabetes.
However, the underlying causes remain unclear. Oxidative stress is considered to
be a major contributor to the development of diabetic nephropathy. NADPH
oxidase is a major source of reactive oxygen species (ROS) in the kidney and
contributes to renal damage in diabetes.
Methods: Nox1-/yApoE-/- or Nox4-/-ApoE-/- and their respective wild type or
ApoE-/- mice were rendered diabetic via streptozotocin injection. ApoE-/- non-
diabetic and diabetic mice were treated with the specific NOX inhibitor
(GKT137831). Animals were culled after 20 weeks and kidneys were removed for
assessment of structural damage, oxidative stress markers, as well as protein
expressions extracellular matrix (ECM), pro-fibrotic and pro-inflammatory
markers. In vitro, Nox4 was silenced in human podocytes and exposed to high
glucose and TGF-b for gene expression analysis and ROS measurements.
Results: Deletion of Nox4, but not of Nox1 resulted in renal protection from
glomerular injury as evidenced by attenuated albuminuria, preserved renal struc-
ture, reduced glomerular accumulation of ECM proteins as well as attenuated
glomerular macrophage infiltration. Administration of GKT137831 to diabetic
ApoE-/- mice conferred a similar degree of renoprotection as did deletion of Nox4.
In human podocytes, silencing of the Nox4 gene resulted in reduced ROS pro-
duction and down-regulation of profibrotic markers that are implicated in dia-
betic nephropathy.
Conclusions: Collectively, these results identify Nox4 is a key source of ROS
responsible for kidney injury in diabetes and provide proof of principle for an
innovative small molecule approach to treat and/or prevent DN.
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EFFECT OF SODIUM RESTRICTION ON BLOOD
PRESSURE, FLUID STATUS AND PROTEINURIA
IN CKD PATIENTS: RESULTS OF A RANDOMISED
CROSSOVER TRIAL AND 6-MONTH FOLLOW-UP
E MCMAHON1, J BAUER2, C HAWLEY3, N ISBEL3, M STOWASSER3,
D JOHNSON3, K CAMPBELL3
1Princess Alexandra Hospital, The University of Queensland, Australia; 2The
University of Queensland, Australia; 3Princess Alexandra Hospital, Australia
Background: High-quality evidence to support the efficacy of sodium-restriction
for reducing cardiovascular risk in CKD patients is needed.
Aim: The aim of this study was to examine in CKD patients 1) the degree of
blood pressure (BP) and proteinuria reduction achievable on a low- versus high-
sodium diet, and 2) whether these benefits are maintained with longer-term
sodium-restriction.
Methods: The LowSALT CKD study was a double-blind randomised-crossover
trial (period-1) with 6-month follow-up (observational arm; period-2). Stage
III-IV CKD patients with BP 130–169/70 mm Hg consumed a low- and
high sodium intake (median 75 [interquartile range (IQR) 58–112] versus
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168 [146–219] mmol sodium/day) each for 2-weeks in random order (period-1).
Participants were counselled to continue a low-sodium diet (target <100 mmol/
day) with outcomes measured again at 6-months (period-2). Primary outcome
was 24-hour ambulatory BP; secondary outcomes were proteinuria and extracel-
lular fluid (ECF, bio-impedance). Outcomes were analysed using paired t-test
where normally distributed and Wilcoxon signed-rank test with non-normal
distribution.
Results: Twenty patients (age 68  11 years and eGFR 31.6  10.6 ml/min/
1.73 m2) completed the study. In period-1, mean ambulatory SBP/DBP was
reduced by 9.8 [95% confidence interval (CI)] 4.5–15.1] /4.0 [1.6–6.4] mm Hg
(P < 0.01), and ECF by 0.8 [95% CI 0.4–1.2] L (P < 0.01) from high- to low-salt
period. At 6-months, SBP/DBP reductions were maintained (increase of 1.3 [95%
CI -4.8-7.3]/1.2 [-1.5-3.9] mm Hg (P > 0.05) when compared with low-sodium
period), as was ECF (P > 0.05). Median protein/albumin excretion were reduced
by 40–50% in period-1 and this was maintained at 6-months (P > 0.05).
Conclusions: Sodium restriction considerably reduced BP, ECF and proteinuria
in CKD patients, and, with the assistance of ongoing dietary-counselling by an
accredited dietitian, these benefits were maintained at 6-months.
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BLOCKADE OF SPLEEN TYROSINE KINASE (Syk)
INHIBITS ANTIBODY-MEDIATED REJECTION IN
RAT RENAL ALLOGRAFTS
S RAMESSUR1, F MA1, G TESCH1, N WOODMAN1, Y HAN1,
K BLEASE2, W MULLEY1, J KANELLIS1, D NIKOLIC-PATERSON1
1Monash Medical Centre, Australia; 2Celgene, Australia
Aim: To determine whether spleen tyrosine kinase (Syk) plays a role in acute
renal allograft rejection.
Background: Kidney allografts induce strong antibody responses which contrib-
utes to graft rejection. Syk is involved in the antibody response (via B-cell
receptor signalling) and antibody-dependent activation of macrophages and neu-
trophils (via FcgR signalling), whereas Syk is not expressed by T-cells. However,
the role of Syk in these responses has not been investigated in allograft rejection.
Methods: Groups of 6 Sprague-Dawley rats underwent bilateral nephrectomy
and an orthotopic transplant with a MHC mis-matched Wistar rat kidney.
Groups of 6 recipient rats were treated with a Syk inhibitor (CC-482417, 30 mg/
kg/bid) or vehicle from 1 hr before surgery until killed on day 5. Isografts controls
were used.
Results: Vehicle treated recipients developed severe allograft failure (serum
creatinine 304  130 vs 46  7 umol/L in isograft; P < 0.001). Histologic
damage included glomerular and peritubular capillaritis, tubular injury (tubulitis,
necrosis, dilation) affecting 90  9% of tubules, and T-cell, macrophage and
neutrophil infiltration. Immunostaining identified Syk activation in infiltrating
leukocytes. Allografts showed IgG and C4d deposition and circulating donor-
specific antibodies (DSA) were identified by flow cytometry. CC-482417
improved allograft function (serum creatinine 149  18 umol/L; P < 0.05 vs
vehicle), with reduced tubular damage (47  19%; P < 0.001) and a reduction in
capillaritis. CC-482417 treatment did not affect T-cell infiltration or activation
(IL-2, granzyme B, IL-2Ra). However, CC-482417 reduced macrophage and
neutrophil infiltration by 40 and 45%, respectively (P < 0.05 vs vehicle), and
reduced macrophage activation (NOS-2, TNF-a, MMP-12). Interestingly,
CC-482417 reduced serum DSA levels by 60% (P < 0.01).
Conclusion: This study establishes the involvement of Syk in antibody-
mediated, but not T-cell mediated, acute renal allograft rejection. Further studies
should examine Syk inhibition in a specific model of AMR.
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CALCIPROTEIN-ASSOCIATED FETUIN-A
CONCENTRATION IS ASSOCIATED WITH
ALL-CAUSE MORTALITY IN PATIENTS WITH
PRE-DIALYSIS CKD
E SMITH1, L TOMLINSON2, M FORD3, E BODENHAM3, L MCMAHON1,
CI RAJKUMAR3, S HOLT1
1Monash University, Australia; 2Cambridge University Hospitals NHS Foundation
Trust, United Kingdom; 3Brighton and Sussex Medical School, United Kingdom
Aim: To assess whether serum calciprotein-associated fetuin-A (CPP Fet-A)
concentrations are predictive of death in a cohort of patients with pre-dialysis
Chronic Kidney Disease (CKD).
Background: Serum CPP Fet-A concentrations have emerged as a potential
marker of extraosseous mineralisation stress in patients with CKD or chronic
inflammatory disease. In vitro studies in the macrophage suggest that CPP are
pro-inflammatory and pro-apoptotic at high levels. In CKD, higher CPP Fet-A
concentrations are associated with a pro-calcific milieu and aortic stiffness. Data
relating CPP Fet-A concentrations to hard outcomes are lacking.
Methods: Serum CPP Fet-A concentrations were measured in a prospective
cohort of 200 patients with Stages 3 and 4 CKD at enrolment. Participants were
followed for a median 5.3 years until death or the observation period ended. Cox
proportional hazards models were used to evaluate the association between serum
CPP Fet-A and death, after adjustment for demographic, renal, mineral and
inflammation-related risk factors.
Results: Mean  SD age was 69  11 years, estimated GFR (eGFR) was
33  11 mL/min/1.73 m2, serum phosphate was 1.08  0.20 mmol/L and CPP
Fet-A was 27.5  21.2 mg/L. During follow-up 43 patients died. After adjustment
for age, gender, eGFR, proteinuria, serum albumin, calcium, phosphate and intact
parathyroid hormone concentrations, a 1SD increase in CPP-Fet-A was associ-
ated with 36% higher risk of all-cause mortality (Hazard ratio, HR 1.36, 95%
confidence interval CI 1.06 to 1.74, P = 0.017). However, addition of high-
sensitivity C-reactive protein to this model significantly attenuated the effect size
(HR, 1.07 95% CI 1.01 to 1.14, P = 0.040).
Conclusions: Serum CPP Fet-A concentration is an inflammation-related risk
marker for all-cause mortality in patients with pre-dialysis CKD.
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CX3CR1-DEC205 DC-TARGETED DNA VACCINE
INDUCES SPECIFIC ANTIBODIES AND LIMITS
ATHEROSCLEROSIS AND MACROPHAGE
INFILTRATION IN THE Apo-E KNOCKOUT MOUSE
MODEL OF ATHEROSCLEROSIS
J ZHOU1, YM WANG1, VWS LEE2, GY ZHANG1, H MEDBURY3,
H WILLIAMS3, Y WANG2, DCH HARRIS2, SI ALEXANDER1,
AM DURKAN1
1Centre for Kidney Research, Children’s Hospital at Westmead, Australia; 2Centre
for Transplantation and Renal Research, The University of Sydney at Westmead,
Australia; 3Vascular Biology Research Centre, Surgery, The University of Sydney,
Westmead Hospital, Australia
Aim: To assess the effect of Dendritic Cell (DC)-targeted CX3CR1 vaccination
in the prevention of macrophage infiltration and attenuation of atherosclerosis in
Apo-E-/- mice.
Background: Monocytes/macrophages are involved in the pathogenesis of
atherosclerosis. CX3C chemokine ligand 1 (CX3CL1/Fractalkine) and its recep-
tor CX3CR1 have been identified to have an important role in the migration and
recruitment of monocytes during the pathogenesis of atherosclerosis.
Methods: DC-targeted and control vectors with CX3CR1 (DEC-CX3CR1/Con-
CX3CR1) were generated. Apo-E -/- mice were vaccinated weekly (3x). Anti-
CX3CR1 antibody was determined by ELISA. Whole aortas were dissected at 34
weeks of age. Severity of atherosclerosis, macrophage infiltration and lipid depo-
sition were examined histologically.
Results: DEC-CX3CR1 vaccinated mice had high levels of anti-CX3CR1 anti-
bodies (Abs 1.1), Con-CX3CR1 vaccinated mice also had increased antibodies
(Abs 0.85), compared to controls (Abs 0.1) (p < 0.001). DEC-CX3CR1 and
Con-CX3CR1 vaccinated mice demonstrated a decreased plaque size
(39%&46% of luminal area) as compared to the control (58%) in brachio-
cephalic artery (p < 0.001, p < 0.05). In the aortic arch, DEC-CX3CR1 vacci-
nated mice showed a significantly decreased plaque size (7.5%) compared to
Con-CX3CR1 vaccinated mice (16%) and control (18%), (p < 0.05, p < 0.01
respectively). Both DEC-CX3CR1 and Con-CX3CR1 vaccinated mice had a
significantly decreased infiltration of macrophages (19%&21% of plaque area)
into the atherosclerotic plaques in comparison to controls (40%, p < 0.05,
p < 0.001 respectively). DEC-CX3CR1 vaccinated mice revealed a significantly
lower lipid deposition level (9% of plaque area) within the atherosclerotic
plaques compared to Con-CX3CR1 mice (14%, p < 0.05) and controls (16%,
p < 0.001).
Conclusions: DC-targeted CX3CR1 vaccination induced specific antibodies
that limit macrophage infiltration into atherosclerotic plaques suggesting a poten-
tial therapeutic role in atherosclerosis.
16 NEPHROLOGY 2013; 18 (SUPP. 1)
© 2013 The Authors
Nephrology © 2013 Asian Pacific Society of Nephrology, 18 (Supp. 1), 15–77
008
BENEFITS AND COSTS OF AN ACCEPTABLE
HUMAN LEUKOCYTE ANTIGEN MISMATCH
PROGRAM IN AUSTRALIA
HD NGUYEN1, G WONG2, K HOWARD3, FHJ CLAAS4, J CRAIG2,
S FIDLER5, L D’ORSOGNA5, J CHAPMAN6, A IRISH5, P FERRARI7
1Sir Charles Gairdner Hospital, Australia; 2The Children’s Hospital at Westmead
and Centre for Transplant and Renal Research, Australia; 3The University of
Sydney, Australia; 4Leiden University Medical Centre, Netherlands; 5Royal Perth
Hospital, Australia; 6Westmead Hospital, Australia; 7Fremantle Hospital, Australia
Aims: To determine the benefits and costs of implementing an acceptable mis-
match program in Australia.
Background: Implementation of an acceptable mismatch program in Europe has
improved access to transplantation for highly-sensitised patients on the deceased-
donor waiting list, but the benefits and costs of a similar program in Australia is
unclear.
Methods: Using a third party perspective, two probabilistic decision analytical
models were developed to compare 1) an eplet-defined acceptable mismatch and
2) and eplet/Luminex-defined acceptable mismatch program with the current
deceased-donor allocation model in Australia (n = 10,000, age 18+). The model
terminated when all transplant recipients were deceased.
Results: Compared with current allocation, an eplet-defined acceptable mis-
match model reduces average waiting time for 4 of 28 (14%) highly-sensitised
recipients by 34  22 months (p = 0.056), with an average gain of 1.32 life-days
and $622 savings per patient; whereas an eplet/Luminex-defined acceptable mis-
match model reduces the average waiting time for 12 of 23 (52%) highly-
sensitised recipients by 37  33 months (p = 0.03), with an average 6.00 life-days
gained and $2,805 savings per patient. Average increase in waiting time for
reallocated recipients in the eplet and eplet/Luminex models were 12  9 and
15  18 months respectively. Among non-highly-sensitised patients on the wait-
list, there was a reduction of 0.09 life-days and $59 excess cost in the eplet-defined
acceptable mismatch model and a reduction of 0.60 life-days and $374 excess cost
in eplet/Luminex-defined acceptable mismatch model.
Conclusions: The integration of an acceptable mismatch program into the
deceased-donor kidney allocation reduces waiting-time and provides modest
health benefits and cost savings for highly-sensitised patients without incurring
significant reduction in overall health benefits and extra costs for non-highly-
sensitised candidates on the waitlist.
009
THE ASSOCIATION BETWEEN GLOMERULAR
FILTRATION RATE ESTIMATED BY MULTIPLE
METHODS AT DIALYSIS COMMENCEMENT AND
PATIENT SURVIVAL IN THE IDEAL TRIAL
MG WONG1, C POLLOCK1, B COOPER1, P BRANLEY2, J COLLINS3,
J CRAIG4, A PILMORE5, J KESSELHUT1, D HARRIS6, DW JOHNSON7
1Department of Renal Medicine, Royal North Shore Hospital, Sydney Medical
School, Australia; 2Monash Medical Centre and Eastern Health Renal Units,
Australia; 3Department of Medicine, The University of Auckland, Auckland City
Hospital, New Zealand; 4Department of Nephrology, Children’s Hospital at
Westmead, Sydney School of Public Health, Australia; 5School of Health and Social
Development, Deakin University, Australia; 6Centre for Transplantation & Renal
Research, Westmead Millennium Institute, University of Sydney, Australia; 7Centre
for Kidney Disease Research, The University of Queensland at Princess Alexandra
Hospital, Brisbane, Australia
Background andAims: The InitiatingDialysis Early and Late (IDEAL) study demon-
strated that planned early or late initiation of dialysis, based on the Cockcroft and
Gault (CG) estimation of glomerular filtration rate (eGFR), was associated with
identical clinical outcomes. This study was a pre-specified analysis examining the
association of all-causemortality with eGFR,measured by theCG,Modification of
Diet in Renal Disease (MDRD) or the Chronic Kidney Disease-Epidemiology
Collaboration (CKD-EPI) formulae at the time of commencement of dialysis.
Methods: IDEAL trial participants were allocated into tertiles according to the
CG, MDRD and CKD-EPI formulae at dialysis commencement. The patient
survival was assessed using the Kaplan-Meier method.
Results: There was no difference in survival among patients when stratified into
tertiles of GFR according to the CG formula. However, there was a significant
survival benefit in the tertile of patients starting dialysis with the lowest eGFR
when the MDRD or CKD-EPI was applied (p < 0.01), independent of correction
for body surface area. An increased hazard ratio for death was observed in older
females and patients with diabetes and cardiovascular disease independent of the
formula used.
Conclusion: Discrepancies exist in the relationship between eGFR at dialysis
commencement and mortality in patients with stage 5 CKD depending on the
formula used. Patients commencing dialysis with a higher eGFR were more likely
to be older, Caucasian and have a history of ischemic heart disease, suggesting
that observational studies demonstrating a survival benefit in patients who start
dialysis ‘late’ is due to reduced comorbidity.
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THE SLO-NIACIN TRIAL: A DOUBLE-BLIND
PLACEBO CONTROLLED RANDOMISED
CROSS-OVER TRIAL OF LOW DOSE
SLOW-RELEASE NIACIN TO LOWER PHOSPHATE
IN HAEMODIALYSIS PATIENTS
K TAN1, D VARDESH2, P RAMAN2, J PETRIE3
1Renal Unit, Logan Hospital, Australia; 2Department of Medicine, Logan Hospital,
Australia; 3Renal Unit, Princess Alexandra Hospital, Brisbane, Australia
Aim: Is low dose slow-release niacin better tolerated but still effective at lower-
ing phosphate?
Background: Serum phosphate levels correlate with mortality in dialysis
patients. Current phosphate binders often cause side-effects leading to poor
compliance. Niacin has previously been shown to lower serum phosphate in
patients with kidney disease. However, at doses previously used (1 g daily), it is
poorly tolerated. Slo-niacin® is a slow-release low-dose formulation (500 mg)
taken once daily.
Method: The study was a double-blind placebo-controlled randomised cross-
over trial approved by the local ethics committee. Patients were on haemodialy-
sis. All patients received both active treatment and placebo for 8 weeks each with
intervening 2 week washout phase. All patients continued usual phosphate
binders and Cinacalcet/vitamin D analogues, although no dose adjustments were
allowed during the study. Patients were recruited if they were >18 yo, not preg-
nant and serum phosphate 4 weeks prior to commencement was 1.8 mM. All
gave informed consent.
Results: 33 patients were recruited. 1 patient died following emergency cardiac
surgery during placebo phase but had not taken trial medication for 2 weeks prior.
32 patients were analysed by intention to treat, including 3 drop-outs (2 Slo-
niacin®, 1 placebo, p = NS). Mean change in serum phosphate over 8 weeks was
-0.23 mM (95% CI -1.29 to 0.81) for niacin versus 0.13 mM (95% CI -0.82 to
1.08) for placebo (p = 0.021, paired t-test). Mean absolute change was thus
>0.3 mM decrease in serum phosphate in favour of niacin. ANOVA of mean
absolute change was also statistically significant at p < 0.007.
Slo-niacin® was well tolerated apart from early mild flushing.
Conclusion: Low dose slow-release niacin remains effective at lowering serum
phosphate and is reasonably tolerated.
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BUTTONHOLE CANNULATION AND INFECTION
OUTCOMES: SYSTEMATIC REVIEW AND
META-ANALYSIS
S KOTWAL1, C MUIR1, C HAWLEY2, K POLKINGHORNE3,
P SNELLING4, M GALLAGHER1, M JARDINE1
1The George Institute for Global Health, Australia; 2Princess Alexandra Hospital,
Australia; 3Monash Medical Centre, Australia; 4Royal Prince Alfred Hospital,
Sydney, Australia
Aims: To summarise the current evidence on the impact of buttonhole cannu-
lation on infection rates.
Background: Publications in the last decade have reported the utilization of
buttonhole cannulation (BH) method for vascular access, especially in the home
haemodialysis population. Some have reported an association with increased
infections in comparison to ropeladder (RL) cannulation, although definitive
evidence is lacking.
Methods: We searched Medline, EMBASE, the clinical trials registry (www
.clinicaltrials.gov) and reference lists of review articles and trials for cannulation
studies in maintenance haemodialysis patients comparing BH with alternative
cannulation methods without language restriction. “Renal dialysis” and “cath-
eterization” were used as MeSH terms while “buttonhole cannulation” as a text
term. Randomised clinical trials (RCT’s) and observational studies between 1950
and 15/Feb/2013 were included. The primary outcome was access-related infec-
tion. Relative risk (RR) or incidence rate ratios (IRRs) with associated 95%
confidence intervals (CI) were calculated or reported IRR used. Random effects
models were used to calculate overall effect estimate and 95% CI’s.
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Results: Thirteen studies, all published after 2006, met the inclusion criteria, 3
RCTS and 10 observational studies, studying a total of more than1472 patients.
Of these, 9 reported total infections, 3 reported systemic infections only and 1
reported local infections only. The majority of studies were single center. Com-
pared with RL cannulation, BH cannulation increased access-related infection
6-fold (RR 6.41, 95%CI 1.43–28.67) in RCT’s, 3 fold (RR 2.95, 95%CI 1.85–
4.71) in studies reporting outcomes before and after change of cannulation
method and 3 fold (RR 3.27, 95%CI 1.44–7.43) in observational studies com-
paring units with different cannulation methods.
Conclusions: Buttonhole cannulation is associated with increased infection risk
and should be used with caution.
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UTILITY OF “BACK UP” ARTERIO-VENOUS
FISTULAS IN PATIENTS ON PERITONEAL
DIALYSIS AND USE OF CENTRAL LINES:
A COMPARISON BETWEEN TWO
AUSTRALIAN CENTRES
N RAO1, M BORLACE1, R TAYLOR1, Y MATTHEW1, L JAFFREY2,
D JOHNSON2, D MUDGE2, K BANNISTER1
1Royal Adelaide Hospital, Australia; 2Princess Alexandra Hospital, Australia
Aim: To study utility of back up arterio-venous fistulas (AVF) in patients initi-
ated on peritoneal dialysis (PD) and to determine the rates of central venous
catheter (CVC) use in patients requiring conversion to haemodialysis (HD).
Background: There is limited data on benefit of back-up AVF in patients treated
with PD and it has been argued that these may not be useable at the time of HD
transfer. There is therefore a high rate of CVC use in this population when they
require transfer to HD.
Methods: We retrospectively analysed data on patients transferred to HD from
PD, between January 2008 and December 2012 at both Royal Adelaide Hospital
(RAH), where a policy of AVF in most PD patients is followed, and Princess
Alexandra Hospital (PAH), where only patients at risk have back up AVF
created.
Results: Of the142 patients at RAH, 33 (23%) patients required transfer to HD.
25 patients had back-up AVF, which was successfully used in 22 patients (88%).
CVC had to be used in 3 patients (12%) as the fistula was dysfunctional. The
CVCs used during transfer at RAH were 11 (33%).Of the 232 patients at PAH,
70 (30%) required transfer. AVF was utilized in 26 (37%) patients, whereas a
CVC had to be used in 44 (61%) patients. Routine creation of AVF in PD
patients was associated with a catheter usage rate of 24% (RAH) as compared to
a rate of 61% (PAH) in a centre where this is not done (P = 0.0006, Fisher’s exact
test).
Conclusion: Routine creation of a back-up AVF in all PD patients is sustainable
and results in a much lower rate of CVC use on HD transfer.
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FETUIN-CONTAINING CALCIPROTEIN PARTICLE
LEVELS CAN BE REDUCED BY DIALYSIS, SODIUM
THIOSULPHATE AND PLASMA EXCHANGE.
POTENTIAL THERAPEUTIC IMPLICATIONS?
M CAI1, E SMITH2, C BRUMBY3, L MCMAHON2, S HOLT4
1Monash Medical Centre, Australia; 2Monash University, Australia; 3Eastern
Health, Australia; 4Royal Melbourne Hospital, Australia
Aim: Determine which, if any, clinical treatment strategies cause a reduction in
Fetuin-A (Fet-A) calciprotien particles (CPP) in dialysis patients.
Background: Fetuin-A is an important regulator of physiological and pathologi-
cal mineralisation. Fetuin-A (Fet-A) has been shown to protect from ectopic
mineralisation. In patients with chronic inflammation and with chronic renal
impairment, Fet-A is detectable within large macromolecular complexes called
calciprotein particles (CPP). These are composed of nanocrystals of calcium
phosphate surrounded by a predominantly Fet-A protein ‘shell’. CPP formation
may protect cells against the pro-inflammatory and pro-apoptotic effects of naked
crystalline calcium phosphate, but may themselves be proinflammatory. We have
previously demonstrated that in calciphylaxis, a condition associated with severe
vascular calcification and a very poor prognosis, a very high proportion of serum
fetuin-A circulates as CPP (CPP%). Treatment of the condition is hindered by
the lack of a reliable target to monitor and we wonder if serum CPP% might be
a useful biomarker.
Methods: We determined whether include increased duration/frequency of
haemodialysis (HDx), sodium thiosulphate (STS) infusion , plasma exchange
(PEx) or transplantation were associated with a sustained reduction in CPP%.
Results: HDx reduces serum CPP% but not sustainably so. The addition of STS
infusion during HDx further reduced CPP%, but infusion between HDx sessions
had no significant sustained reduction. PEx provided additional benefit, reducing
CPP% between HDx sessions. Transplantation resulted in sustained lower levels
of CPP%.
Conclusion: CPP% may be a modifiable marker of mineral stress. Experiments
are being conducted to determine whether CPP are directly involved in the
pathology of vascular calcification.
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USE OF STENTS IN HAEMODIALYSIS FISTULAE:
SUCCESS AND LONG TERM FOLLOW-UP
B NEUEN1, R BAER2, JP KILLEN2, M MANTHA2
1James Cook University School of Medicine and Dentistry, Australia; 2Renal
Services, Cairns Base Hospital, Australia
Aim: Endovascular stent deployment is used to treat dysfunctional haemodialy-
sis fistulae characterized by resistant or recurrent stenosis and pseudoaneurysms.
This study aims to report the procedural success, complication rate and long-term
patency of stents in haemodialysis fistulae at a single centre.
Background: The use of self-expandable bare metal and covered stents have
been described to treat resistant or recurrent stenosis, to obliterate large pseu-
doaneurysms and as a bailout technique to deal with complications related to
angioplasty procedures. The effectiveness of these procedures has been described
in the literature with varying degrees of success.
Methods: Between 2008 and 2012, 50 procedures (9 for pseudoaneurysms, 41 for
resistant or recurrent stenoses) were performed in 42 patients at a single centre.
Clinical and radiological information collected during this period was reviewed
retrospectively. Post-intervention primary and secondary (cumulative functional)
patency rates were determined using Kaplan Meier analysis. Patients were cen-
sored for death, loss to follow-up and transplantation.
Results: The clinical and anatomical success rate was 98% (49/50). Minor
complications that did not affect procedural success occurred in 3 instances. A
major complication leading to access loss occurred in one procedure. Post-
intervention primary patency rates at 6, 12 and 18 months were 52%, 24% and
10% respectively. Post-intervention secondary patency rates at 6, 12 and 18
months were 98%, 92% and 92% respectively, with an additional 1.7 procedures
per patient.
Conclusion: The use of stents in haemodialysis fistulae provides excellent func-
tion patency of the dialysis fistulae but repeated procedures are required to
maintain secondary patency.
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UPPER ARM FISTULAE AND MULTIPLE
STENOSES INFLUENCE HAEMODIALYSIS
ARTERIOVENOUS FISTULAE PATENCY AFTER
BALLOON ANGIOPLASTY
B NEUEN1, R GUNNARSSON1, R BAER2, JP KILLEN2, F GRAINER2,
M MANTHA2
1James Cook University School of Medicine and Dentistry, Australia; 2Renal
Services, Cairns Base Hospital, Australia
Aim: Patency after percutaneous balloon angioplasty (PTA) for haemodialysis
fistula stenosis is highly variable. This study aimed to assess factors associated with
patency following first episode of treatment with PTA.
Background: Restenosis recurs commonly after PTA. Previous studies have
shown that some intrinsic fistula and biochemical factors may influence patency
after PTA.
Methods: We retrospectively reviewed all endovascular procedures performed by
nephrologists between 2007 and 2012 at a single centre. Anatomical, clinical,
biochemical and medication information was subjected to cox regression analysis
to identify factors influencing post-intervention patency.
Results: 120 patients were identified as having first episode treatment with PTA.
During a median follow-up period of 22.66 months (5.24–53 months), 171
follow-up procedures were performed. Post-intervention primary patency rates at
6, 12 and 18 months were 46%, 25% and 15% respectively. Cumulative (func-
tional) patency rates at 6, 12 and 18 months were 97%, 94 and 92% respectively
with 1.4 additional procedures per patient. In univariate cox regression analysis,
the presence of multiple lesions (p = 0.037) was associated with early restenosis
at 6 months, while upper arm fistulae were associated with early restenosis
(p = 0.004) and shorter primary patency (p = 0.001). Other anatomical charac-
teristics (fistula age, lesion length, pre-procedure stenosis), clinical history
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(diabetes, coronary and peripheral artery disease), medications, and biochemical
parameters (HbA1c, CRP, albumin and lipids) did not influence patency.
Conclusion: Multiple stenoses and upper arm fistulae may be associated with
shorter patency after PTA. More large volume prospective studies are required to
further assess factors associated with patency after PTA in haemodialysis fistulae,
particularly the role of metabolic and inflammatory markers.
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CLINICAL OUTCOMES AFTER ARTERIOVENOUS
FISTULA CREATION IN PATIENTS WITH
CHRONIC KIDNEY DISEASE
M LEE, P MOUNT, M ROBERTS, M ROSS-SMITH, J CHUEN
Austin Health, Australia
Aim: Creation of an arteriovenous fistula (AVF) before initiation of haemodi-
alysis (HD) is an important goal in chronic kidney disease (CKD) management.
This study aims to determine outcomes and optimal timing for AVF creation in
CKD patients.
Methods: We reviewed records of all CKD patients who had a first AVF creation
for future HD at Austin Health from 01/01/2007–31/12/2009 and obtained
follow-up data until 31/12/2011. Survival analysis was performed for the primary
outcome of time from AVF creation to first HD treatment.
Results: In 100 patients who had a first AVF created, the mean age was
63.7  13.7 years, 49 had diabetes and 39 were female. Mean time from AVF
creation to first HD in 73 patients who commenced HD was 14.1  12.7 (range:
0.2–47.7) months. Of these 73 patients, 21 (29%) required a radiological and/or
surgical procedure before commencing HD and 26 (36%) required a procedure
within 3 months of commencing HD. Despite AVF creation, 12 (16%) patients
required a catheter to start HD and 2 (3%) required a catheter within 3 months
of HD commencement. Median time to starting HD was 479 days. In patients
with eGFR < 16 mL/min (the median) median time to starting dialysis was
321 days compared to 909 days for eGFR  16 ml/min (Log rank p = 0.018).
At 3, 6 and 12 months respectively, 20%, 44% and 56% of patients with
eGFR < 16 mL/min had commenced HD compared to 11%, 20% and 26% with
eGFR  16 ml/min.
Conclusion: While early AVF creation is an important goal, we demonstrate
that optimal timing of AVF creation is challenging, with half of our patients not
using the AVF for over a year, and many requiring subsequent AVF procedures
before becoming established on HD.
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OUTCOME OF PREDIALYSIS EDUCATION IN
WESTERN SYDNEY: EARLY REFERRAL IS
ASSOCIATED WITH REDUCED RATE OF LINE USE
AT FIRST DIALYSIS
T SMOLONOGOV, YM KUANG, L KAIRAITIS
Western Renal Service, Australia
Aim: To review characteristics and outcomes for patients referred to a compre-
hensive predialysis programme in Western Sydney.
Background: In 2005 theWestern Renal Service (WRS) appointed a Predialysis
coordinator to facilitate patient education, informed dialysis modality choice and
facilitate access planning. This programme was developed to promote home
dialysis therapies and minimise rates of unplanned dialysis commencement and
haemodialysis catheter use as initial dialysis access.
Methods: Patients referred for predialysis education between 2005–2010 and
who subsequently commenced dialysis were identified from the WRS predialysis
database. The proportions of these patients who ultimately undertook a home
dialysis therapy or commenced dialysis with permanent access were calculated
and related to the GFR at referral to this programme.
Results: 965 patients were referred to the predialysis programme in this period.
546 of these patients subsequently commenced maintenance dialysis; 72% of this
group ultimately undertook a home dialysis therapy. The average referral GFR
was 12.5 mL/min/1.73 m2, 74% were referred with a GFR of 15 mL/min/1.73 m2
and 92% with a GFR of 20 mL/min/1.73 m2 or less.
Patients who started dialysis with permanent dialysis access had a higher GFR
at referral than patients who commenced dialysis with a haemodialysis catheter
(13.4 vs 11.1, p < 0.01). Patients referred for predialysis interview with a GFR
more than 10 ml/min/1.73 m2 were more likely to commence dialysis with per-
manent dialysis access (p < 0.01). Rates of home dialysis did not appear to be
affected by the GFR at time of referral.
Conclusions: Despite the referral GFR being lower than recommended levels,
high rates of home dialysis uptake was achieved in patients referred to the
predialysis programme at WRS. Earlier referral is associated with a higher chance




AFTER BALLOON ANGIOPLASTY; A
SYSTEMATIC REVIEW
B NEUEN1, A WEBSTER2, R GUNNARSSON1, R BAER3, JP KILLEN3,
M MANTHA3
1James Cook University School of Medicine and Dentistry, Australia; 2Sydney
School of Public Health, The University of Sydney, Australia; 3Renal Services,
Cairns Base Hospital, Australia
Aim: Percutaneous transluminal angioplasty (PTA) is an established treatment
for haemodialysis fistula stenosis. This study aimed to systematically review evi-
dence for factors associated with patency after percutaneous transluminal angi-
oplasty (PTA).
Background: The effects of patient comorbidity, demographic, biochemical and
anatomical characteristics, with initial PTA success and post-intervention
patency have not previously been summarised.
Methods: We searched databases to identify studies assessing patency after PTA
in haemodialysis fistulae. Studies of immature or thrombosed fistulae or other
dialysis access were excluded. Quality of studies was assessed using a modified
validated checklist. Outcomes assessed were post-intervention primary and sec-
ondary patency, restenosis at 6 months, technical and clinical success, assisted
primary patency and mean interval or frequency of endovascular interventions
during follow up. Findings were summarized descriptively.
Results: We included 12 single-centre studies of 1 120 participants with 1281
fistulae. Follow-up ranged from 3 days-10years. Shorter primary patency was seen
with more recent fistulae (4 studies), longer stenosis length, upper arm fistulae (2
studies), small inflow artery diameter, arteriovenous anastomotic site and history
of previous endovascular interventions (1 study each). Shorter secondary patency
was seen with increased patient age (2 studies), and more recent fistulae (1 study).
Early restenosis was associated with diabetes (3 studies), HbA1c, low-density
lipoprotein, and asymmetric dimethylarginine (1 study each). Technical success
was reduced for upper arm fistulae and high-grade stenoses (1 study), while
clinical success of PTA was more likely in stenotic compared to thrombosed
fistulae (1 study).
Conclusion: Fistula characteristics and diabetes may be associated with poor
PTA outcomes, however evidence is inconclusive, and the role of metabolic and
inflammatory markers is unclear.
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IMPROVING VASCULAR ACCESS OUTCOMES AT
GOLD COAST
S THOKALA, D DU TOIT, T SNOW, M JACKSON, J KURTKOTI,
A PARNHAM, M DIVI, T TITUS, B HIREMAGALUR
Gold Coast Hospital, Australia
Background: A mature arteriovenous fistula (AVF) at the start of dialysis
reduces morbidity, mortality and costs compared to a cental venous catheter
(CVC). In 2005, less than 38% of our patients commenced haemodialysis with an
AVF and Central Line Associated Blood Stream Infection (CLABSI) rate asso-
ciated with our haemodialysis CVC’s was 3.5/1000 catheter days.
Aim: A multi-pronged intervention was developed with focus on a renal access
co-ordinator to expedite a “fistula first” approach and reduce complications asso-
ciated with HD CVC use by targeting incident (first dialysis) catheter rates and
CLABSI rates.
Methods: Outcome was assessed by 1. Proportion of patients starting dialysis
with a CVC. 2. Tunnelled Haemodialysis associated CLABSI rates per 1000
catheter days. 3. Proportion of patients on maintenance dialysis with a CVC. 4.
Non tunnelled haemodialysis catheter total yearly dwell days. 5. Proportion of
prevalent patients and incident patients with AVF.
Results: The proportion of patients commencing haemodialysis via a CVC
dropped from 62% in 2005 to 34% in 2012. The CLABSI Rate associated with
tunnelled Haemodialysis catheter use dropped from 3.5/ 1000 days in 2005 to
0.35/ 1000 days in 2012. The percentage of patients on maintenance haemodi-
alysis via a CVC dropped from 13% in 2005 to 9% in 2012. The non-tunnelled
CVC line days per year dropped from 1330 line days/ yr in 2006 to 220 line days/
yr in 2012. The percentage of incident patients with AVF improved from 15% in
2007 to 35.7% in 2012, and prevalence rate from 76% to 88%.
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